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The ﬁrst effective therapy for exudative macular degeneration (AMD) was Photodynamic Therapy (PDT).
Diagnosis of the disease was to a large extent by ﬂuorescein angiography (FA). Distinguishing between
the leaky choroidal neovessels (CNV) associated with exudative AMD, and the polypoidal structures
associated with Polypoidal Choroidal Vasculopathy (PCV) is not always easy using FA alone. The switch to
Indocyanine Green angiography helped to pinpoint PCV, and thus to study the efﬁcacy of photodynamic
therapy of this particular form of retinal disease, which is more frequently encountered among pig-
mented individuals. The results appear to be quite promising, and in the year following treatment only a
small fraction of the patients had to be retreated. Alternatively, treating PCV with repeated intravitreal
VEGF blocking agents was not as successful as it was in the treatment of wet AMD. However, combining
PDT-induced angio-occlusion of the polypoidal lesions with anti-vascular endothelial growth factor
therapy was shown to be quite effective, and the combination of PDT with an anti-angiogenic agent as
well as a steroid, in a triple therapy, was recently also shown to be a quite promising option. In the
present article we review the data on PDT of PCV, including combination therapies and alternative
treatments. We also report on similarities and differences between AMD and PCV.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
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Photodynamic therapy (PDT) was introduced in ophthalmology
in the late 1990s as a treatment for choroidal neovascularization
(CNV) secondary to age-related macular degeneration (AMD)
(Schmidt-Erfurth et al., 1998; van den Bergh, 2001). PDT with
Visudyne as a photosensitizer was the ﬁrst effective and safe
treatment for subfoveal lesions, saving up to now more than a
million eyes from legal blindness (Blumenkranz et al., 2002;
Bressler et al., 2002; Bressler and Treatment of Age-Related Mac-
ular Degenerationwith Photodynamic Therapy Study, 2001). CNV is
encountered in patients with exudative AMD, but also occurs in
pathologic myopia, inﬂammation, angioid streaks, trauma and
choroidal rupture (Koh et al., 2011; Koh and Haimovici, 2004).
Although wet AMD constitutes only a small fraction (10%e15%) of
AMD, it is the major cause of blindness of the elderly in the western
world (Ambati et al., 2003). CNV often develops in or near the fovea,
the central part of the macula, where the leaking vessels lead to
edema, and ﬁnally scar tissue, which may replace the photore-
ceptors. Themaintenance of healthymacular function is dependent
on the integrity of the different layers of the retina and the asso-
ciated functional biochemical processes. These layers include the
choroid, Bruch’s membrane, the retinal pigmented epithelium
(RPE), the photoreceptors and Müller cells, and the neural retina
which preprocesses the visual information, before sending it via the
ganglion cells, the axons, the optic nerve and the lateral geniculate
nucleus, to the visual cortex of the brain. The etiology of CNV sec-
ondary to AMD is still not completely known (Kevany and
Palczewski, 2010; Young, 1967). The photoreceptor outer seg-
ments that include a stack of phospholipid membrane discs con-
taining the opsins, which are responsible for the initiation of
phototransduction, and which accumulate oxidative stress in the
vision process. A key component in this photo-oxydation being all-
trans-retinal, an intermediate in the visual retinoid cycle, which
interacts with UV and blue light to produce reactive oxygen species
(ROS) including O2, O21D and peroxides. These ROS react with
proteins and lipids changing their chemical structure and hence
their function (Maeda et al., 2012). Part of these outer segments
contains many discs that are then periodically shed. The shed outer
segment (OS) fragments are then phagocytosed and destroyed by
lysosomal degradation in the neighboring RPE cells. The oxidized
compounds are less well degraded by the lysosomal enzymes,
which leads to deposits of a fatty material called lipofuscin in and
under the RPE. Such deposits, consisting of among others retinoid
conjugates may show up as whitish spots during ophthalmoscopy,
are called drusen. Blue light excitation of lipofuscin can lead
to further oxidation, which may induce inﬂammation andangiogenesis. Also the decreased transport of oxygen, liquid and
nutrients due to these lipophilic deposits can lead to hypoxia, the
induction of HIF-1a (hypoxia-inducible factor 1-alpha) and VEGF-A
(vascular endothelial growth factor-A) and hence neo-angiogenesis
and vascular sprouting from the choroid into Bruch’s membrane.
Some of the possible causes for the accumulation of toxic pig-
ments in and around the RPE that are related to defects in the visual
retinal cycle taking place both in rods and cones, are shown sche-
matically in Fig. 1 for the case of rod opsin (Kevany and Palczewski,
2010; Travis et al., 2007; Young, 1967). This cycle is based on the
photo-isomerization of 11-cis-retinaldehyde (11-cis-RAL), the main
visual chromophore, to all-trans-RAL, which leads to conformational
changes in rhodopsin. This, in the end, leads to activation of the
phototransduction cascade. The all-trans-RAL must then be recycled
to 11-cis-RAL in order to restore the visual pigment, otherwise vision
would not be maintained. This recycling, in the case of rod photore-
ceptors, starts in the outer segments, and then goes via the RPE cells
back into the rods. The cone retinal cycle needs to bemuch faster than
in the case of rods, i.e. up to 106/sec for the replacement of 11-cis-RAL,
but its exact mechanism still needs to be conﬁrmed (Wang and
Kefalov, 2011). It probably involves retinoid cycling from the cone
outer segment to a neighboring Müller cell, and then via the cone
inner segment back to the cone outer segment. In parallel, another
retinoid cone cycle also starts in the cone outer segment, but passes
via a number of processes in the neighboring RPE back to the cone
outer segment. Another important difference between the two types
of photoreceptors is that rod discs are separated from the inter-
photoreceptor matrix by the rod plasma membrane. The cone discs
communicate more directly with this interphotoreceptor space. This
morphologic difference yields a more open structure and an
increased outer surface of the cone discs, which helps to enhance the
rates of exchange between cone and close lying RPE andMüller cells.
All these retinal cycles involve a number of enzymes for the necessary
chemical and conformational changes, aswell as important transport
proteins (Almasieh et al., 2012; Saari, 2012; Wielgus and Roberts,
2012). Mutations that inﬂuence these enzymes and transport pro-
teins, can change theﬂowof the retinoidsandcause theaccumulation
of toxic retinoids, aswell as byproducts, thus leading tovarietyof age-
related and other diseases. The currently unknown etiology of Poly-
poidal ChoroidalVasculopathy (PCV)maywell include, amongothers,
disrupted retinoid cycling, possibly in relation to genetic mutations
causing changes in the enzymes or proteins involved in this cycling
process.Asanumberof genetic alterations that correlatewithPCVare
now becoming known, and are reported on below, urgent animal
experiments are needed to investigate this.
Choroidal vessels are often classiﬁed as “occult” CNV when they
are restricted to the area in and around Bruch’s membrane, below
Fig. 1. The simpliﬁed retinoid cycle between a rod and an RPE cell. (A) shows schematically part of the retina including photoreceptors, outside of the macula mainly rods and in the
macula mainly cones. Below the photoreceptors are the retinal pigmented epithelium (RPE), Bruch’s membrane and the choroid. Not shown are the Müller cells and the amacrine,
horizontal, and bipolar cells, i.e. the neural retina, which preprocesses the optical signals generated by the photoreceptors, nor the ganglion cells. It should be noted that the density
of photoreceptors is quite high in the macula and that many photoreceptors can be associated with each RPE cell. (B) shows the simpliﬁed visual retinoid cycle between a rod and an
RPE cell *). This cycle is essential to sustain continuous vision. It replenishes the main visual chromophore 11-cis-retinaldehyde (11-cis-RAL), which is bleached by visible and UV
light. The replenishment is a cyclic process, which involves a number of enzymes and transport proteins. More precisely, light activation of rhodopsin, located in the discs of the
outer segment of the rod cell, causes the isomerization of 11-cis-RAL to all-trans-RAL. This in turn activates the opsin, which after some conformational changes yields meta-
rhodopsin II (MII). This induces further processes that lead to hyperpolarization of the rod cell and the visual transduction cascade. After deactivation of the MII, it separates into
apo-opsin and an all-trans-RAL molecule. The latter is released in the inner leaﬂet of the disc bilayer where it can reversibly complex with phosphatidylethanolamine (PE) to yield
retinylidene-PE (N-ret-PE), which is then “ﬂipped” across the disc membrane by the transporter ABCA4. The all-trans-retinal can now be released from N-ret-PE to the rod
cytoplasm. The all-trans-RAL itself can likewise be transported from the intradiscal space to the rod cytoplasm by ABCA4 where it is reduced by all-trans retinol dehydrogenase
enzymes (all-trans-RDH’s) to the alcohol (all-trans-ROL) with the help of NADPH. All-trans-ROL then moves out of the rod cell, binds to a protein (IRBP) to avoid degradation in the
extracellular space before being endocytosed into an RPE cell, where it binds strongly to another protein (CRBPI). The alcohol is then esteriﬁed to all-trans-retinal-ester (all-trans-
RE) by LRAT (lecithin-retinol acyl transferase). This all-trans-RE in the RPE cells can be increased to some extend by (i) all-trans-retinol (vitamin A) diffusing from the choroidal
capillaries, and by (ii) all-trans-ROL from the above-mentioned phagocytosis of the shed outer segment fragments. All-trans-ROL from, both of these pathways can be esteriﬁed by
LRAT to all-trans-RE. The all-trans-REs in the RPE cells are regarded as one of the “reserves” of retinoids in the visual cycle. Then a single enzyme (Rpe65) accomplishes both the
trans-to-cis isomerization, as well as the hydrolysis, of the esters, to yield 11-cis-retinol, which binds to a protein (CRALBP) to avoid self-inhibition of the reaction by the cis-alcohol
product. The 11-cis-ROL bound to CRALBP can then either be esteriﬁed by LRAT to form another form of retinoid cycle storage, as the cis-ester, or it can be oxidized to 11-cis-RAL by a
dehydrogenase (RDH) with the help of the co-factor NAD. The 11-cis-RAL then leaves the RPE, combines with IRBP for protection and re-enters the rod cell to complete the cycle by
joining with the apo-opsin thus reforming the visual pigment. This “stored” reserve of 11-cis-RE in the RPE cell canwhen necessary be returned to the retinoid cycle by reactionwith
the ester hydrolase 11-cis-REH. The main reason for giving the above somewhat detailed description of the retinoid cycle is that at every step in this cycle things can go wrong and
each error may lead to a speciﬁc disease. The red arrows indicate one example of such a damage pathway, where under increased light conditions more all-trans-RAL is produced so
that N-ret-PE combines more oftenwith a second all-trans-RAL to form A2PE and ﬁnally the ﬂuorescing product A2E. This molecule may end up in the lipofuscin deposits (“drusen”)
that are often associated with retinal damage. The second (thicker) red arrow pathway leading towards “DAMAGE” implies directly the all-trans-RAL. Enough of this molecule needs
to be present to sustain the retinoid visual cycle. However an excess of all-trans-RAL is closely correlated with retinal degeneration. Reduced clearance of all-trans-RAL from the rod
OS, for instance by insufﬁcient activity of the all-trans-RDH enzymes, may lead to enhanced production of A2E and lipofuscin. Enhanced levels of free-trans-RAL, which produces
ROS when activated by UV/blue light, furthermore induces OS disc oxidation, leading to decreased lysosomal degradation of the phagocytosed discs in the RPE, and build-up of
lipofuscin. Photolysis of the latter can ﬁnally lead to the release of pro-inﬂammatory and pro-angiogenic factors, and blinding disease. The blue arrows indicate the normal retinoid
cycle with associated proteins and enzymes. The gray arrows indicate the storage of 11-cis-RE. Adapted from Maeda et al. (2006); Nowak-Sliwinska (2012); Travis et al. (2007). *) As
there are signiﬁcant differences between the light sensitivity and response time of rods and cones, the mechanism of the visual retinoid cycle is also bound to show differences
between these two kinds of photoreceptors, i.e. cycling must be signiﬁcantly faster in cones. Here we show some details of the retinoid recycling between rods and RPE cells only, as
the recycling mechanism for cones is less well established. It has been suggested to include Müller cells, as well as RPE cells, see also (Travis et al., 2007; Wang and Kefalov, 2011).
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slower loss of vision than is the case for the co-called “classic” CNV.
The occult CNV are also relatively harder to visualize during ﬂuo-
rescein angiography, due to the fact that the excitation and emis-
sion wavelengths are strongly absorbed by the melanin in the RPE.
Alternatively the CNV are sometimes capable of transgressing the
RPE (Koh et al., 2011), thus making themmore visible in ﬂuorescein
angiography. These CNV are often associated with optically well-
deﬁned areas of leaking blood vessels that are called “classic”
CNV. They are visible early-on in the ﬂuorescein angiography, and
are involved in the more severe and faster vision loss. All CNV are
pathologically and functionally abnormal, leaking lipids, ﬂuid and
blood into the surrounding retina, causing edema and retinalthickening which can be observed and quantiﬁed in high-
resolution optical coherence tomography (OCT), and is often asso-
ciated with vision impairment.
If the CVN leakage extends over longer times it can lead to scar
tissue in the retina and scotoma, i.e. dark regions in our central
vision. The size and number of drusen can be correlated with dis-
ease progression and has been used as a predictor for patient
outcome (Liu et al., 2011). CNV and its treatment by Visudyne-
photodynamic therapy (V-PDT) have been described extensively
in the literature (Jirarattanasopa et al., 2012; Miller, 2010; Schmidt-
Erfurth et al., 1994, 1998; van den Bergh, 2001). The results of CNV
treatment with PDT alone in clinical trials, or of PDT in combination
with other treatment modalities, are described in detail elsewhere
le 1
mary of clinical trials with V-PDT for choroidal neovascularization.
udy Treatment regimen Follow up
period
(months)
Results Ref.
P V-PDT* 24 V-PDT reduced the risk of moderate or severe vi s in
patients with CNV due to AMD.
(Kaiser, 2006)
P V-PDT* (Northern America, Europe) 24 In the V-PDT group, VA improvement by minim
5 letters was observed in patients with CNV due t
pathologic myopia.
(Blinder et al., 2003)
m et al. V-PDT* (Asian patients) 24 Median VA improvement was 1.7 lines, but the m
number of V-PDT retreatments required in the ﬁ
2 years was 2.3 - lower than in the VIP study.
(Lam et al., 2004)
CHOR Ranibizumab (0.3 mg or 0.5 mg) vs. V-PDT* 12 Ranibizumab was superior to V-PDT with respec
to both VA and anatomic (lesion size and
CNV leakage) outcomes.
(Brown et al., 2006)
CUS V-PDT* (quarterly) þ 7 days later Ranibizumab
0.5 mg monthly; vs. V-PDT*þ7 days later
sham injections monthly
24 At 24 month, 88% of patients on V-PDT þ Ranibi
versus 75% of those on V-PDT alone had a vision
inferior to 15 letters in visual acuity. 25% of cases
combination arm versus 7% of the PDT alone pati
gained at least 15 letters.
(Schmidt-Erfurth et al., 2008)
OTECT Same-day V-PDT* vs. þ ranibizumab 0.5 mg 12 Same-day administration of V-PDT* and ranibizu sulted
in the mean improvement in VA of 6.9 letters and ers at
4 and 9 months of follow-up, respectively.
(Spitzer et al., 2008)
ONT BLANC V-PDT*; vs. ranibizumab 0.5 mg 12 VA improvements in the combination group are n rior to a
ranibizumab alone with three ranibizumab doses d by
injections on a monthly regimen.
(Cook and Figg, 2010)
ENALI V-PDT* þ ranibizumab 0.5 mg; vs. V-PDT**
þ ranibizumab 0.5 mg; vs. ranibizumab 0.5 mg
12 DENALI did not demonstrate non-inferior visual a in
for V-PDT combination therapy compared with mab
monthly monotherapy.
(Couch and Bakri, 2011)
DICAL V-PDT** þ within 2 h ranibizumab (0.5 mg)
þ dexamethasone (0.5 mg); vs. V-PDT***
þ ranibizumab (0.5 mg) þ dexamethasone (0.5 mg);
vs. ranibizumab only (0.5 mg)
24 Cumulative retreatment rates were lower in all ation
groups compared with the ranibizumab monot group.
Mean VA change from baseline was not statistica ent
among the treatment groups.
(Hudson, 2008)
LIO V-PDT* (light applied 30 min after the start of
verteporﬁn infusion)
12 Improved VA and angiographic outcomes with an ble
safety proﬁle compared with standard light appli
15 min after the start of the infusion
(Rosenfeld et al., 2007)
IPLE THERAPY V-PDT****, 16 h later dexamethasone (800 ug)
þ bevacizumab (1.5 mg)
9 Only less than 25% of the patients treated with th
regimen required additional treatment.
(Augustin, 2009)
V-PDT* þ immediate injection of bevacizumab
(1.25 mg) þ TA (4 mg), þ bevacizumab
(1.25 mg) every 3 months
6 These short-term results (6 months) demonstrate
resolution by single triple therapy in 77.8% of trea s
(Yip et al., 2009)
Same-day V-PDT** þ dexamethasone (200 ug)
þ bevacizumab (1.5 mg)
13.7 VA was maintained, decreased macular thickness
treatment-naïve or eyes previously treated with a F. The
mean number of repeat triple therapy treatments in
both mentioned groups.
(Bakri et al., 2009)
V-PDT**, immediate dexamethasone (800 ug)
þ bevacizumab (1.5 mg) at 1 and 7 weeks later
12 VA improved from 0.53 to 0.74. The mean numbe tment
cycles was 1.4. The mean number of bevacizumab ns was 2.8
(Ehmann and Garcia, 2010)
ndard ﬂuence: 50 J/cm2, 83 s, 600 mW/cm2 at 689 nm, Visudyne injection/light application time interval of 15 min; **Reduced ﬂuence: 25 J/cm2, 83 s, 300 mW 689 nm; ***Reduced ﬂuence: 15 J/cm2, 83 s, 180 mW/
at 689 nm; ****Reduced ﬂuence: 42 J/cm2, 300 mW/cm2 at 689 nm; TA: triamcinolone acetonide; VA: visual acuity; V-PDT: Visudyne-photodynamic thera
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et al., 2003; Hudson, 2008; Kaiser, 2006; Lam et al., 2004; Lee et al.,
2008b; Schmidt-Erfurth et al., 2008; Spitzer et al., 2008; Yip et al.,
2009) and are summarized in Table 1.
While comparing the clinical trial results obtained in the
treatment of what was thought to be the CNV associated with
exudative AMD, signiﬁcant differences in the visual acuity outcome
were observed between Asian and Caucasian patients. In fact, the
responses to photodynamic therapy were better in Japanese pa-
tients (JAT trial) as compared to Caucasian patients (TAP trial)
(2003), see Fig. 2. Exactly the same therapy (same drug, same in-
jections, same drug-light interval, same light ﬂuence and intensity,
same patient inclusion/exclusion criteria, same way of evaluation
the VA, etc.) in Japanese patients diagnosed with exudative AMD
gave better visual acuity gain vs. sham than in the Caucasian pa-
tients that had also been diagnosed with exudative AMD (Honda
et al., 2009; Negrier and Raymond, 2012; Yamashita et al., 2010).
Historically, with the use of indocyanine green angiography
(ICGA) atypical cases of AMD had been found, with a vascular
network that terminates in polypoidal lesions. These lesions were
called polypoidal choroidal vasculopathy (PCV). PCV was recog-
nized and reported for the ﬁrst time in 1982 by Yannuzzi and col-
leagues as an uncommon hemorrhagic disorder of the macula
(Ciardella et al., 2004). Two years later similar retinal changes
named “posterior uveal bleeding syndrome” were observed by
Kleiner et al. (Kleiner et al., 1990). In 1985, Stern and colleagues
characterized multiple, bilateral, serosanguineous retinal pigment
epithelium detachments occurring in African woman (Stern et al.,
1985). Five years later Yannuzzi and collaborators introduced the
term “idiopathic PCV”, since the observed pathogenesis of sub-
retinal, polypoidal vascular lesions associated with hemorrhagic
RPE detachments was at that time unknown (Yannuzzi et al., 1997).
From the comparison of V-PDT results between Japanese and
Caucasian patients it became clear that the V-PDT trials on what
had been identiﬁed by ﬂuorescein angiography as wet AMD had
inadvertently included cases of PCV. The darker skinned patients
have a higher percentage of PCV then their Caucasian counterparts,
and the better visual acuity outcome in the JAT trial was thus
interpreted to be associated with the possibility of a more effective
photodynamic treatment of PCV as compared to PDT of exudative
AMD.Fig. 2. Comparison of the mean change in visual acuity found after different treat-
ments of wet AMD. ANCHOR (V-PDT; 50 J/cm2, 600 mW/cm2 with/without 0.3 mg or
0.5 mg ranibizumab), JAT (V-PDT in Japanese patients with subfoveal choroidal
neovascularization secondary to AMD) and TAP (Japanese patients; V-PDT; 50 J/cm2,
600 mW/cm2) trials. Month zero stands for the baseline.2. Mechanism of action of Visudyne-photodynamic therapy
Visudyne-PDT (V-PDT) is a treatment that utilizes the endo-
thelial concentration of a photoactivable compound or photosensi-
tizer (PS) in the CNV shortly after a 10-min i.v. infusion of 6 mg/m2 of
liposomal benzoporphyrin derivative monoacid ring A (BPDMA). It
should be noted here that part of the selectivity of this treatment, as
determined by Visudyne ﬂuorescence angiography, is due to the
difference inpharmacokinetics of the drug, shortly after the injection,
between the retinal and choroidal capillaries (van den Bergh et al.,
2004; Van den Bergh, 2003). The “standard” protocol of local light
delivery (light dose of 50 J/cm2, irradiance of 600mW/cm2 of 689 nm
light over 83 s, starting 15min after the beginning of the i.v. infusion)
produces a vaso-occlusive effect. CNV damage from PDT generally
depends on the photosensitizing agent and the treatment regimen
used. Photodynamic damage caused by illumination of a PS shortly
after its injection is mostly observed in the endothelium and sub-
endothelium (van den Bergh and Ballini, 2003). The endothelial cell
damage, originates at the endothelial luminal surface andbeginswith
the inﬂuxof calcium into the cells (Foster et al.,1991). This increase in
the cytosolic calcium concentration leads to conformational changes
in adhesionmolecules andmodiﬁcations in the cytoskeleton, such as
the depolarization of cytoplasmic microtubules. This is followed by
cell shape alterations, such as rounding and contraction (Nelson et al.,
1987). Contraction of endothelial cells results in the loss of tight
junctions between these cells and the exposure of the vascular
basement membrane (Schmidt-Erfurth et al., 1994) to circulating
blood, and the local activation of von Willebrand factor (vWf). The
subsequent interaction of blood platelets with the denudated
vascular wall induces the activation and aggregation of platelets.
Platelets have also been shown to accumulate PSs and upon irradia-
tion are damaged, losing serotonin and ATP proportional to the PS
dose administered (Solomonet al.,1966; Zieve et al.,1966). In theend,
platelet damage and the interaction of platelets with pro-coagulant
extracellular matrix components and the damage to the endothe-
lium lead to vessel constriction and thrombus formation via Ca2þ
exchange between pericytes and the endothelium (Henderson et al.,
1992; Nelson et al., 1987; Reed et al., 1988).
The adhesion of granulocytes has also been observed following
endothelial cell damage. This can induce increased vascular
permeability and edema (Fingar, 1996). Damage to platelets further
stimulates the release of thromboxane and leukotriene B4, both of
which contribute to enhanced vascular permeability and the
disruption of the endothelial cell lining of exposed blood vessels
(Doukas et al., 1989; Klausner et al., 1989). Endothelial cells may
also inﬂuence the blood clotting balance through the release of
clotting factors (Ben-Hur et al., 1988), including vWf (Foster et al.,
1991). All of these biochemical changes disrupt the balance of
platelet pro-aggregatory/vaso-constricting compounds and anti-
aggregatory/vaso-dilating agents (Chang and Petry, 1980;
Ogletree, 1987), resulting in smooth muscle constriction and
further platelet aggregation. In a parallel mechanism, PDT-induced
damage to membrane lipids elicits the release of arachidonic acid,
which initiates a series of reactions, also ending in the release of
thromboxane. Vessel constriction is further supported by the in-
hibition of nitric oxide production in endothelial cells (Gilissen
et al., 1993). Finally, a blood clot within the vessel lumen can
potentially cause obstruction to blood ﬂow (stasis), leading to the
termination of vascular function. In summary, PDT depending on
the applied conditions, can either lead to blockage of the vascula-
ture, or to enhanced leakage from the vasculature, or to both. In the
present application, PDT of PCV, one tries to select conditions that
are optimal for the selective closure of the PCV.
The most important factor determining the outcome of PDT is
how the photosensitizer interacts with the cells within the target
Fig. 3. Representative images of PCV visualized by ICG angiography (AeD). The nodular polypoidal structures are clearly shown on early ICGA within an indentation in the margin
(also known as a “notch”) of a large hemorrhagic pigment epithelial detachment. A hypoﬂuorescent halo around these nodular structures is characteristic of PCV, and helpful in
diagnosis when present. There is increasing hyperﬂuorescence through the mid and late phases of the ICGA, with late leakage and staining of the entire PCV complex. The fellow eye
shows late staining from an inactive PCV complex.
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organelles such as the mitochondria, lysosomes, endoplasmic re-
ticulum, Golgi apparatus and plasmamembranes (Pazos and Nader,
2007). Water-soluble photosensitizers may predominantly bind to
lysosomes, leading to release of cathepsins and necrosis (Hamblin
and Mroz, 2008) or autophagy (Kessel and Oleinick, 2010). Verte-
porﬁn, as a somewhat more hydrophobic compound, mainly lo-
calizes in mitochondria and at the time of light delivery generates
reactive oxygen species (ROS) causing the disruption of the mito-
chondrial membrane. The latter probably causes the opening of the
mitochondrial permeability transition pore complex (PTPC), which
leads to the secretion of cytochrome-c into the cytosol.
Cytochrome-c forms an apoptosom, a multi-protein complex, with
apoptosis-activation factor 1 and ATP. The latter activates pro-
caspase 9, and then the apoptosom releases caspase 9 that ﬁnally
induces caspase 3, which is a key protein in the induction of
apoptosis. A more detailed description can be found in van den
Bergh and Ballini (van den Bergh and Ballini, 2003) or others
(Hamblin and Mroz, 2008) (Robertson et al., 2009).
3. Epidemiology and clinical characteristics of polypoidal
choroidal vasculopathy (PCV)
3.1. Epidemiology
PCVwas often found to be themain vascular disorder in patients
of pigmented races diagnosed with neovascular maculopathies,
especially African-Americans and Asians (Ciardella et al., 2004)
(Wen et al., 2004). PCV is also frequent in the Japanese population.
PCV occurs in white patients (Imamura et al., 2010), but to a
signiﬁcantly lesser extent. Japanese clinical studies suggested that
54.7% of the patients with neovascular age-related macular
degeneration also have PCV (Maruko et al., 2007). The age-
distribution at which PCV is diagnosed is also different from that
of wet AMD. Indeed PCV is usually diagnosed in patients between
50 and 65 years old, but the age of diagnosis may range between 20
and more than 80 years. Caucasians seem to have more female
cases of PCV, while in Asia it is more the male population that is
affected (Kwok et al., 2002; Wen et al., 2004). The presence of PCV
in one eye generally indicates a high risk for bilateralism (Ciardella
et al., 2004).
3.2. Clinical characteristics
The main clinical characteristic of PCV is the presence of early
focal nodular hyperﬂuorescence detected by means of indocyanine
green angiography (ICGA). The latter is the gold standard for thediagnostic of this disease (Koh et al., 2012). The longer excitation
and detection wavelengths for ICG ﬂuorescence, as compared to
those used in ﬂuorescein angiography, can penetrate the RPE easier,
allowing improved imaging (see Fig. 3).
In early-phase ICGA, the choroidal PCV vessels are dilated
(Chung et al., 2011) and the area around polypoidal vessels remains
hypoﬂuorescent. Subsequently, small hyperﬂuorescent polyps
become visible in the choroid. The late phase ICGA is associated
with reversed ﬂuorescence observations as compared to the early
phase, i.e. the area surrounding the polypoidal lesions becomes
ﬂuorescent and the center of the lesions becomes hypoﬂuorescent
(Spaide et al., 1995).
The reason for choroidal hyperpermeability as detected by ICG
angiography in PCV is still not well known. OCT images, giving a
cross-sectional view of the retina and the choroid, showed that the
polypoidal structures are located beneath the RPE (Iijima et al.,
2000; Imamura et al., 2010). While the branching vascular
network may be quiescent in some cases of PCV, it can remain the
main cause of leakage and exudation in other patients. One of the
main advantages of ICGA is that ICG is highly protein bound, and
the larger molecular complex does not leak easily from the cho-
riocapillaries, allowing clear deﬁnition of the vascular structures
within the choriocapillaries. Retina Angiography (RA) during the
ﬁrst minute transit phase, using a scanning laser ophthalmoscope
(SLO) from Heidelberg allows for a clear deﬁnition of the branching
vascular network, delineation of the polypoidal structures, and
furthermore allows for the exclusion of retinal angiomatous pro-
liferation (RAP). The latter is an important mimic of PCV. Lastly, ICG
is used to guide the PDT treatment zone. PCV is characterized by a
branching vascular network originating from the inner choroid that
terminates in polypoidal lesions (Ciardella et al., 2004). Another
clinical manifestation of PCV is the presence of serosanguineous
RPE detachments in the region of the central macula or around the
optic nerve. These lesions may bleed, causing vitreal hemorrhage,
which potentially can lead to vision loss (Fig. 4).
PCV is usually detected only after serosanguineous detachment
of the RPE, or vitreous hemorrhage, but with less ﬁbrous scarring
compared to choroidal neovascularization (Yannuzzi et al., 1990,
2012). Another feature is the presence of degenerated small arte-
rioles and capillaries with a thickened basement membrane. The
polypoidal lesions range from small to large and perfuse branching
inner choroidal vessels (Cackett et al., 2009).
Another feature of the PCV is a hyalinization of the choroid-
based vessels. The latter refers to the replacement of smooth
muscle tissue due to elevated intraluminal pressure or elastin
coding gene (ELN) dysfunction (Kondo et al., 2008). Other histo-
pathological features included plasma and/or ﬁbrin exudation
Fig. 4. Massive subretinal, preretinal and vitreous hemorrhage is an uncommon but striking presentation of polypoidal choroidal vasculopathy (PCV). (A) Color fundus image
showing massive submacular hemorrhage due to peripapillary PCV visible in image B, not visible on the color photographs alone. Some patients experience massive subretinal
hemorrhage (C & D) that result in breakthrough vitreous hemorrhage and even total blindness and phthisis bulbi, as reported previously (Ojima et al., 2006; Tan et al., 2007).
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hemorrhage, or associated with a branching vascular network
(BVN). PCV can also be characterized by orange subretinal nodules
that are visible stereoscopically in the color fundus photograph.
Subfoveal choroidal thickness is greater in eyes with choroidal
hyperpermeability than that in eyes without it, both in wet AMD
and PCV, whereas in eyes without choroidal hyperpermeability, the
mean subfoveal choroidal thickness was greater in PCV than that in
typical exudative AMD (Jirarattanasopa et al., 2012).
Identiﬁcation of PCV as early as possible in the therapeutic
sequence provides timely information on longer-term disease
behavior and can often lead to a change in treatment strategy. OCT,
giving cross-sectional images of the choroid and neural retina,
helps to identify PCV by detecting the abnormalities surrounding
PCV (Iijima et al., 2000). In OCT, PCV is characterized by a higher
incidence of serohemorrhagic pigment epithelium detachments
(PED), greater PED height, and less intraretinal edema than eyes
with exudative AMD (Ozawa et al., 2009). OCT images demonstrate
that polypoidal structures exist beneath the RPE and they tend to
be found attached to the back surface of RPE, see Table 2 (Imamura
et al., 2010; Laude et al., 2010). Thus PCV is often found in the sub-
RPE space in wet AMD specimens. Giovannini et al. found in all
cases reported a characteristic hyper-reﬂectivity in the choroidal
layers (Giovannini et al., 1999). These ﬁndings may be a key dif-
ference in the characteristics of PCV and wet AMD. Therefore, the
systematic OCT scans are useful in order to provide the proper
diagnosis. This might have a particular importance for already
treated patients, in order to maintain the best treatment outcome
during the long-term follow up period. In patients with seros-
anguineous detachment of the pigment epithelium, particularly
thosewith increased risk factors, such as African-American or Asian
race, ICGA and OCT should both be performed to evaluate the
choroidal vascular abnormality in an attempt to establish a more
deﬁnitive diagnosis.4. Natural history of PCV
Polypoidal choroidal vasculopathy develops slowly and was
shown to persist for a long time. Therefore the natural history of
this disorder, as observed in a large series of patients was unclear
(Yannuzzi et al., 1997). In the study performed on Japanese elderly
patients by Uyama et al. two patterns of the clinical manifestation
of PCV were observed: exudative PCV and hemorrhagic PCV
(Uyama et al., 2002). In patients with the exudative pattern,
persistent leakage and repeated bleedings leading to a poor visual
outcome were observed. Serous pigment epithelial detachment
(PED) and retinal detachmentwere predominant at themacula. The
hemorrhagic pattern was characterized by hemorrhagic PED andmacular subretinal hemorrhage. Eyes with PCV that did not un-
dergo treatment had a variable course. About half of the eyes had a
stable course and a relatively favorable outcome. The other half of
the eyes had persistent leakage or repeated bleeding and a poor
visual outcome. Sho et al. reported also severe visual loss incidence,
which was 35% of PCV as compared to 53% in exudative AMD (Sho
et al., 2003).5. Are PCV and neovascular AMD part of the same disease or
are they distinct entities?
PCV associated with subretinal neovascularization was often
mis-diagnosed using ﬂuorescein angiography as wet age-related
macular degeneration (AMD) (Laude et al., 2010; Lim et al., 2012).
Presently, it still remains unclear whether PCV represents a subtype
of neovascularized AMD or a completely separate disorder. Both
diseases share some similarities, like laterality (bilateral), presence
of choroidal neovascularization and some genetic background
(Laude et al., 2010), however only based on the differences
observed between the two diseases can, the proper diagnosis and
treatment be performed (see Table 2). As stated above, the patients
with PCV are mostly Asians or African-Americans and on the
average they are younger than the patients diagnosed with AMD.
Their eyes have considerably less, or even a complete lack of dru-
sen, which are a characteristic sign of AMD (Laude et al., 2010).
Although associated with multiple recurrent serosanguineous
macular detachment, PCV is not linked to signiﬁcant ﬁbrous pro-
liferation as is the case in end-stage neovascular AMD (Jager et al.,
2008). Choroidal thickness turns out to be different in the two
disorders. As identiﬁed using enhanced-depth imaging optical
coherence tomography, i.e. by the measurement of the vertical
distance from the Bruch’s membrane to the innermost scleral layer
(Chung et al., 2011), subfoveal choroidal thickness was thicker in
the eyes with PCV, in contrast to the thinner choroid observed in
eyes with AMD.
The relative importance of vascular endothelial growth factor
(VEGF), an angiogenesis stimulator, and of pigment epithelium
derived factor (PEDF), a protein that inhibits angiogenesis, both of
which are expressed in choroidal neovascular membranes in eyes
with PCV and AMD, also differs between the two diseases.
VEGF and PEDF were shown to be strongly expressed in vascular
endothelial cells and retinal pigment epithelial cells of the excised
subfoveal ﬁbrovascular human CNV tissues (Matsuoka et al., 2004).
Although the expression level of VEGF is increased in both pa-
thologies as compared to the healthy eye, the VEGF level in eyes
diagnosed with PCV was considerable lower than in AMD eyes
(Tong et al., 2006). That may well be one of the reasons why the
response to anti-VEGF treatment in PCV is not anywhere near as
Table 2
Selected similar and differential features of AMD and PCV.
Feature Wet AMD PCV Ref.
Similarities
Laterality Bilateral (Ciardella et al., 2004)
Appearance Abnormal vasculopathy leading to
serous exudation or vitreal hemorrhage
(Imamura et al., 2010)
Treatment Both AMD and PCV can be treated
well with triple therapy
(Imamura et al., 2010)
Genetics Complement factor H (CFH)
High temperature required factor A1 (HTRA1)
Complement component 2/complement
factor B (C2/BF, 6p21)
Complement component 3 (C3, 19p13)
(Chen et al., 2012;
Cheng et al., 2013)
Differences
Location based on OCT Intra Bruch’s membrane Beneath Bruch’s membrane (Ciardella et al., 2004)
Late phase ICGA Lesions located subfoveally;
Weaker hyperﬂuorescence with weaker margins
Lesions located peripapillary
(Caucasians) and extrafoveally
(Chinese); Late geographic
hyperﬂuorescence
(Chen et al., 2012)
Choroidal thickness Thin Thick (Chung et al., 2011)
Fibrous proliferation Yes No (Yannuzzi et al., 1990)
Vessel morphology Larger, leaky vessels Small branching vessels termination in
“polyps”, less leaky vessels
(Green et al., 1985)
Drusen Yes Less or no drusen (Imamura et al., 2010)
Pulsations No Yes (Yuzawa et al., 2005)
Patient proﬁle European, American, also Asian, elderly African-American and Asian,
younger than in AMD
(Imamura et al., 2010)
Grading system Based on the drusen size and number; AREDS
classiﬁcation
Based on the polyp location, size
and number
(Jager et al., 2008)
VEGF and PEDF level Increased Increased, but lower than in AMD (Matsuoka et al., 2004)
Genetics HTRA1, weaker association then in PCV
ELN down-regulation
Rs10757278 on chromosome 9p21* not associated
with the risk of PCV in the Chinese Han patients
HTRA1
ELN up-regulation
LOC387715 rs10490924 signiﬁcantly
associated with PCV
Rs10757278 on chromosome 9p21*
signiﬁcantly associated with the risk
of PCV in the Chinese Han patients
(Chen et al., 2012;
Zhang et al., 2011)
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reporting on the seven-year outcome of ranibizumab-treated
exudative AMD patients, conﬁrmed that despite of the fact that
one third of patients demonstrated good visual outcomes, another
third had poor VA (Rofagha et al., 2013). The conclusion of this
study was that at this timepoint exudative AMD patients still
remain at risk for substantial visual decline in the long term.
The histopathologic characteristics of PCV include hyalinized
vessels, signiﬁcant extravasation of plasma proteins lack of granu-
lation tissue proliferation and deposition of basement membrane-
like material (Nakashizuka et al., 2008; Okubo et al., 2002). More-
over, the foamy CD68-positive macrophages were reported around
the vessel cavity, and HIF-1a positive mononuclear cells are present
in the stroma. Immunoreactive VEGF deposits were present in the
macrophages but not in the vascular endothelial cells. Hyalinized
vessels in PCV are negative for a-SMA expression, although the
pericytes of the vessels in CNV were immunoreactive for a-SMA.
This ﬁnding may indicate that the smooth muscle cells of choroidal
vessels in PCV disappear due to the increased intraluminal pres-
sure. CD34 staining revealed discontinuity in the vascular endo-
thelium in the PCV.
For CNV secondary to AMD only a few CD68-positive cells are
present in the stroma. HIF-1 positive mononuclear cells are located
at macrophages and RPE cells but not at vascular endothelial cells.
Calciﬁcation and fragmentation of Bruch’s membrane was
observed. Soft, and large drusen and basal laminar deposit are
observed that strongly correlate with the histologic presence of
AMD (Spraul et al., 1999).
In PCV ﬁbrosis and proliferation of RPE cells was more promi-
nent than in CNV secondary to AMD. The ﬁbrovascular tissue thatappeared to correspond to the polypoidal lesions was observed
under the RPE cells and contained numerous dilated, thin walled
vessels and massive ﬁbrin-like material (Matsuoka et al., 2004).
The genetics of PCV and AMD has been extensively studied
(Chen et al., 2012; Cheng et al., 2013; Gotoh et al., 2009; Hayashi
et al., 2010; Honda et al., 2012). Age-related eye disease studies
(AREDS) of AMD caseecontrol subjects using 100,000 single
nucleotide polymorphisms (SNPs) resulted in the identiﬁcation of
four chromosomal regions signiﬁcantly associated with the disease,
i.e. the age-related maculopathy susceptibility 2(ARMS2)/Htra
serine peptidase 1 (HTRA1) (10q26), the complement factor H
(CFH) (1q32), the complement component 2/complement factor B
(C2/BF, 6p21), and complement component 3 (C3, 19p13). It was
hypothesized that overexpression of high temperature required
factor A1 (HTRA1), which controls the integrity of Bruch’s mem-
brane, facilitates the invasion of Bruch’s membrane by the CNV (Lee
et al., 2008a). The association between AMD, PCV and three SNPs in
these gene regions rs1061170 (CFH), rs10490924 (ARMS2), and
rs11200638 (HTRA1), were veriﬁed by a number of research groups
both in Caucasians and Japanese patients (Goto et al., 2009; Kanda
et al., 2007). There is a consistent association of the ARMS2/HTRA1
locus with both neovascular AMD and PCV, suggesting the two
diseases at least in part share molecular mechanisms (Cheng et al.,
2013)!
HTRA1 was found to be associated with both disorders, being
about two-fold stronger in AMD than in PCV (Lee et al., 2008a) in
Asian patients. Another susceptibility gene in PCV is the elastin
gene (ELN), which is shown to be more associated with PCV than
with AMD (Kondo et al., 2008). The LOC387715 rs10490924, i.e. the
gene which codes mitochondrial protein in photoreceptors, was
Table 3
Summary of clinical trials with V-PDT alone or in combination with other treatment modalities in PCV in Japanese (J), Asian (A), or European (E) patients.
Treatment regiment Patient
origin
Absolute
follow up
period
(months)
Results Ref.
V-PDT* J 12 VA improved (15 letters or more) in AMD and PCV by 6% and 25%,
respectively. Fluorescein leakage was suppressed in 86% of PCV
and 61% of AMD eyes, respectively.
(Gomi et al., 2008)
V-PDT* J 24 VA preserved or improved in 79% of eyes. Recurrence of polypoidal
lesions in 64% of eyes. An abnormal branching vascular network
persisted in all subjects.
(Akaza et al., 2008)
V-PDT J 19.2 Regression of the polypoidal lesions observed in 94% of eyes. The
branching vascular network remained in all eyes.
(Wakabayashi et al., 2008)
V-PDT* J 12 Signiﬁcantly better response to V-PDT in terms of VA improvement
and effect durability in PCV patients as compared to AMD.
(Honda et al., 2009)
V-PDT** J 12 Signiﬁcantly lower V-PDT frequency and greater improvement in
the visual acuity in PCV lesions as compared to AMD.
(Yamashita et al., 2010)
V-PDT* J 12 The visual acuity improved in 56.3% of patients, remained the same
in 31.3%, and decreased in 12.5% and. No patient had any long lasting
complication after the treatment.
(Spaide et al., 2002)
V-PDT* E 36 Approximately 75% of the treated eyes had no signiﬁcant loss of vision,
and 14.8% showed signiﬁcant improvement in visual acuity.
(Leal et al., 2010)
V-PDT* J 60 Mean VA letter score loss is somewhat longer in patients with AMD
(7.25) as compared to patients with PCV (5.36) at the month 60
examination. More frequent retreatments we necessary in the years
3 and 4 in PCV patients than patients with AMD.
(Tsuchihashi et al., 2013)
V-PDT* þ ranibizumab 0.5 mg A 12 Complete regression of polypoidal lesions in the combination therapy. group. (Tsuchiya et al., 2009)
V-PDT* þ ranibizumab 0.5 mg A 12 The mean BCVA change from baseline wasþ12.3 letters. 58.3% of patients
had a BCVA gain of 15 letters or more. All patients underwent regression
of polyps without recurrence.
(Ruamviboonsuk et al., 2010)
V-PDT* þ bevacizumab 1.25 mg J 12 Lower rate of post V-PDT hemorrhage. Recurrence rate unchanged. (Gomi et al., 2010)
Ranibizumab 0.5 mg þ V-PDT* J 12 Improved VA and reduced exudation. (Saito et al., 2012)
V-PDT** þ bevacizumab 1.25 mg A 12 Improved VA in 56% treated eyes. (Sagong et al., 2012)
Patient origin: Japanese (J); Asian (A); European (E); *Standard ﬂuence: 50 J/cm2, 600mW/cm2 at 689 nm; **Reduced ﬂuence: 25 J/cm2 for 70 s, 300mW/cm2 at 689 nm; BCVA:
best corrected visual acuity; V-PDT: Visudyne-photodynamic therapy.
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distribution in AMD and PCV (Chen et al., 2012). LOC387715
rs10490924 correlates with vitreous hemorrhage, and also with the
lesion size. Rs10757278 on chromosome 9p21 was shown to be
signiﬁcantly associated with the risk of PCV in Chinese Han patients
(Zhang et al., 2011).
6. The role of thermal laser photocoagulation in the
management of PCV
Few reports of laser photocoagulation for PCV have been
described (Gomez-Ulla et al., 1998; Lafaut et al., 2000; Lee et al.,
2009; Yuzawa et al., 2003). Yuzawa et al. (2003) conducted laser
photocoagulation for PCV, targeting only polypoidal lesions in 47
eyes. Intense photocoagulation, over a spot of 200 mm in diameter
during 0.2 s induced a fusion scar. The irradiation was performed
with an argon dye laser or multicolor krypton laser. 9 of 10 eyes that
underwent photocoagulation, targeting the whole lesion, i.e.
including both the network and polypoidal lesions, showed ab-
sorption of the exudate after a single treatment and maintained or
improved vision without recurrence. 20 eyes (54%) showed
decreased vision due to persistent, recurrent exudation and/or
classic CNV, or alternatively due to RPE atrophy. In 32 eyes at least
two, and sometimes more laser treatments were performed.
Clearly multiple treatments were often needed, with longer follow-
up, due to the recurrence of serosanguineous detachment origi-
nating from the remaining (or new) polypoidal lesions. Lafaut et al.
(2000) treated 14 eyes with laser photocoagulation with follow up
over 6 months. 10/14 eyes showed regression of fundus signs
without persisting polyps. In the study of Lee et al. (Lee et al., 2009)
from 28 eyes treated with argon laser photocoagulation, 10/28
showed improvement, 11/28 stabilization, 7/28 loss in the visualacuity outcome at ﬁnal follow up after 12months. At this time point
3/28 eyes had recurrence of polyps. Based on the recent guidelines
for the management of PCV (Koh et al., 2013), direct laser photo-
coagulation is not recommended as an initial therapy for subfoveal
or juxtafoveal PCV, but it still may be used in the treatment of
extrafoveal polyps (Koh et al., 2013; Lee et al., 2009).
7. Photodynamic therapy in PCV
The most effective treatment for polypoidal choroidal vascul-
opathy has not yet been completely established for all cases, but
some trends can already be observed. Visudyne-PDT (V-PDT) is
clearly a safer treatment modality for subfoveal or juxtafoveal AMD
and PCV than thermal laser photocoagulation, mainly due to the
minimal damage done to the retina. PDT has consequently been
used very successfully in treating PCV (Koh et al., 2012).
In the clinical reports on a single treatment of V-PDT of PCV,
with a follow-up of about 1 year, preservation and improvement of
visual acuity was achieved in more than 80% of the mostly Asian
patients (Imamura et al., 2010; Negrier and Raymond, 2012; Spaide
et al., 2002). The summaries of these studies, which are discussed
below, are presented in Table 3.
A prospective interventional study was performed on Japanese
patients (Negrier and Raymond, 2012). Based on indocyanine green
angiography, 36 eyes (39%) were diagnosed with PCV and 54 eyes
(58%) with choroidal neovascularization secondary to AMD. Visual
recovery after V-PDT was reported to be slightly more favorable
for the eyes with PCV (8 letters) than in those with AMD (7.0 let-
ters). The VA improved (15 letters or more) in 6% of the AMD pa-
tients, and in 25% of the PCV patients. The VA decreased (15 letters
or more) in 31% of the AMD patients and in 8%, of the PCV patients.
At 1-year ﬂuorescein leakage was suppressed in 86% of the PCV
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superior results for treating PCV as compared to CNV secondary to
AMD (Negrier and Raymond, 2012) in these patients.
Spaide et al. (2012), in a 1 year retrospective review, reported on
16 patients with subfoveal PCV treated with V-PDT. The visual
acuity improved in 9 (56.3%) of the patients, and remained the
same in 5 (31.3%), and decreased in 2 (12.5%) of the patients. There
were no reported long lasting complications after the treatment.
Themean change in visual acuity was an improvement of nearly 2.4
lines!
Promising results were also found in other studies in Japanese
patients at 1 year after standard ﬂuence V-PDT (Honda et al.,
2009) or reduced-ﬂuence V-PDT (Yamashita et al., 2010, 2012).
In both studies the PCV patients required a signiﬁcantly lower
retreatment PDT frequency, and also demonstrated a greater
improvement in the visual acuity than was the case of the AMD
patients, i.e. fewer PDT treatments per year were needed to obtain
optimal results in the case of PCV than in the case of wet AMD. In
patients with PCV treated with PDT, the recurrence period, i.e. the
treatment-free period until the subsequent required intervention
was signiﬁcantly longer than was the case for wet AMD patients.
Even though all polypoidal lesions regress with PDT, its effect on
the branching network of polypoidal vessels does not seem to be
permanent and thus recurrence of polypoidal lesions may occur in
the long run. Another problem is the heterogeneous localization of
the polyps, especially those in the peripapillary area, which is not
always easily accessible to the laser-based PDT treatment. Repeated
PDT in a minority of cases may induce persistent choroidal atrophy.
In another example, during a 3-year follow up period, a non-
randomized study was conducted involving eyes with newly diag-
nosed PCV, which were treated exclusively with V-PDT (Leal et al.,
2010). Patients were submitted to an average of 3.19 treatment
sessions. In this study, approximately 75% of the treated eyes had no
signiﬁcant loss of vision, and 14.8% showed signiﬁcant improvement
in visual acuity. Although the recurrences were frequent (59.3% of
the eyes at 3 years of follow-up), they respondedwell to retreatment,
and were not associated with increased visual acuity loss.
Other limitations of PDT are occasional pigment epithelium
detachment or the possibility of a large submacular hemorrhage.
Hirami et al. (2007) retrospectively reviewed the data for 91 eyes of
patients who underwent PDT for the treatment of PCV. In this
study, during the follow-up period after PDT, postoperative sub-
retinal hemorrhage was seen in 30.8% of eyes. In 78.6% of these
eyes, the subretinal hemorrhage was absorbed without treatment.
Although visual acuity was the same or increased in 81.8% of eyes
with subretinal hemorrhage alone, it decreased signiﬁcantly in
50.0% of the eyes with postoperative vitreous hemorrhage.
Akaza et al. with a follow-up of 24 months showed regression of
the polypoidal lesions in 29 out of 31 eyes (94%). However, recur-
rence of polypoidal lesions appeared in 10 of 29 eyes (34%) and
additional PDT was suggested. V-PDT could reduce the size of
polypoidal lesions, but did not destroy them completely. Thus, the
persistent branching vessels in the network are supposed to be at
the origin of the new polypoidal lesions (Akaza et al., 2008).
Idiopathic PCV is a disease with heterogeneous presentations,
and the feeder vessel (FV) may be difﬁcult to recognize. FV iden-
tiﬁcation requires high-speed ICG (HSICG) identiﬁcation in order to
analyze blood ﬂow dynamics in the feeder vessels and to select the
optimal treatment area. For treatment of the feeder vessels (FV)
associated with the CNV, V-PDT was performed with a second
light application, after applying the standard dose (50 J/cm2) to the
entire lesion (including a 1000 mm margin), with a second spot of
around 200 mm diameter focused on the feeder vessel itself. This
treatment did not lead to scotoma, and enabled to qualify the pa-
tient for a long-term follow up (Sickenberg M., unpublished data).Similar results were obtained in another study with a follow-up
of 19.2 months (Wakabayashi et al., 2008). After initial V-PDT, the
polypoidal lesions regressed in 94% of eyes, but the branching
vascular network remained in all eyes, and increased in size in 42%
of eyes. Five-year follow up results on very small numbers of V-
PDT in Japanese patients with neovascular AMD and PCV seem to
indicate that the difference in visual prognosis between AMD and
PCV after long-term follow up was small (Tsuchihashi et al., 2013).
Previous reports with a follow up of 12 months showed signiﬁ-
cantly better results for PDT in the treatment of PCV, as compared
to PDT for AMD. This long-term data on a very small number of
patients indicated that there might not be that much difference in
visual prognosis between AMD and PCV patients. PCV patients in
this study had to have marginally more frequent retreatments in
years 3 and 4 when compared to AMD patients.
Rosenfeld et al. reported on the efﬁcacy of standard ﬂuence V-
PDT with delayed light application for exudative AMD (VALIO trial)
(Rosenfeld et al., 2007). There were no statistically signiﬁcant dif-
ferences between V-PDT using the delayed light regimen of
30 min or the standard light regimen applied after 15 min. The
efﬁcacy of this approach, however, needs to be veriﬁed in PCV
patients.
Summarizing, PDT in PCV demonstrated very positive short- to
medium e term results. Retreatment is necessary in some cases,
but at a relatively low frequency. PDT is currently the most effective
and selective means of obliterating polypoidal lesions. The obser-
vations reported above prompted the search for strategies to
improve the efﬁciency and selectivity of V-PDT for polypoidal
retinal lesions and reduce the treatment burden. It should be
underlined here that the Visudyne pharmacokinetic study by van
den Bergh, Ballini and Sickenberg, showed enhanced selectivity
between CNV and retinal capillaries at longer delays between in-
jection and light application. However, normal choroidal capillaries
were also closed by PDT together with the CNV. Further increase in
the selectivity between choroidal and retinal vessels may also be
obtained by shortening the duration of the Visudyne injection.
However the desired improved targeting between CNV and
choroidal capillaries will need a more sophisticated molecular
approach.
7.1. Anti-VEGF therapy in PCV
The efﬁcacy of the antievascular endothelial growth factor
(VEGF) drug bevacizumab (Avastin; Genentech, South San Fran-
cisco, California, USA) is well known for treating CNV secondary to
AMD (Avery et al., 2006); however, its efﬁcacy for treating PCV
seems limited (Imamura et al., 2010). As reported by Gomi et al. 3
months after intravitreal bevacizumab, ICG angiography conﬁrmed
the reduced leakage from PCV but the treatment did not decrease
the choroidal vascular changes. These results suggested that poly-
poidal dilation of choroidal vessels in PCVmay not depend on VEGF
to the same extent as does age-related neovascularization. This may
be correlated with the observation that the VEGF levels in the
aqueous humor in PCV are signiﬁcantly lower than those in neo-
vascular AMD (Tong et al., 2006).
The reasons for differences in anti-VEGF responsiveness in AMD
and PCV are still not well understood. The angiogenic status of the
tissue depends among others on the balance between pro-
angiogenic VEGF and anti-angiogenic epithelium-derived growth
factor (PEGF) (Gao et al., 2001). Matsuoka et al. furthermore
showed that when the subfoveal ﬁbrovascular membranes are
active, both VEGF and PEDF are strongly expressed in the endo-
thelial cells. However, when the subfoveal ﬁbrovascular mem-
branes are in amore quiescent state, both VEGF and PEDF are barely
expressed in the endothelial cells (Matsuoka et al., 2004). This was
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CNVwas active. PEDF and VEGFwere both strongly expressed in the
choroidal neovascular lesions. After the CNV development was
ﬁnished (i.e. quiescent CNV), the expression of both VEGF and PEDF
decreased in the endothelial cells, whereas strong expression of
PEDF was observed in the proliferating RPE cells covering the CNV
(Ogata et al., 2002).
Further studies have been performed with drugs that target
other cytokines. One of these cytokines is platelet-derived growth
factor (PDGF), a vascular maturation factor. The rationale behind
the blocking of PDGF is to interfere with the process of vascular
maturation via the reduction of pericyte recruitment and survival.
The corresponding phase II trial, aiming to assess the efﬁcacy and
safety of a combination treatment regimen (E10030, which is anti-
PDGF compound, plus ranibizumab), is ongoing. Macrophages are
also involved in both AMD and PCV formation. Immunohis-
tochemically, CD68-positive foamy macrophages have been
detected around the hyalinized vessels, but a-smooth muscle actin
(SMA)epositive cells were not. Hyalinized vessels in PCV were
negative for a-SMA expression, although pericytes of vessels in CNV
were immunoreactive for a-SMA (Nakashizuka et al., 2008). These
ﬁndings may indicate that smooth muscle cells of choroidal vessels
in PCV disappear due to the increased intraluminal pressure.
Inﬂammation plays an important role in the pathogenesis of
AMD. Thus immune components, such as complement factors,
macrophages and cytokines are involved in the progression of
AMD. Inﬂammation was observed, indicated by the presence of B
and T lymphocytes, at the level of the choroid and the ﬁbrovascular
tissue and the signiﬁcant presence of intercellular adhesion cyto-
kines like ICAM-1 was shown. The choroidal inﬁltration by in-
ﬂammatory cells was also reported by Rosa et al. (Rosa et al., 2002).
Therefore, anti-inﬂammatory agents, such as steroids, immuno-
suppressive agents or complement inhibitors may provide an
adjuvant efﬁcacy when combined with an anti-angiogenic strategy
(Nowak-Sliwinska, 2012) in this disease.
Several studies reported decreased retinal thickness in PCV
patients observed by OCT following intravitreal injection of bev-
acizumab (Ghajarnia et al., 2007; Lee et al., 2008b). Kokame et al.
wrote that multiple injections of monthly intravitreal ranibizumab,
a humanized, full-length anti-VEGF antibody, werewell tolerated in
PCV patients. Additionally, patients also showed stabilized vision
and decreased macular edema (Kokame et al., 2010). Lai et al.
evaluated the efﬁcacy of intravitreal bevacizumab with or without
V-PDT in the treatment of PCV with themean follow-up duration of
12.8 months. Despite the visual and anatomical improvements,
persistent polyps were present in ICGA of all eyes at 3 months (Lai
et al., 2008). There are also reports on patients with worsening
exudation despite previous anti-VEGF therapy (Cho et al., 2009;
Stangos et al., 2010). Mahesh et al. reported on anti-VEGF treat-
ment in 14 Indian patients with a follow up of 8 months.12 patients
received bevacizumab 1.25 mg, one patient received pegaptanib
sodium 0.3 mg and one patient received 0.5 mg ranibizumab. All 14
patients had worsening of the clinical conditions after treatment
and had to be retreated with thermal laser photocoagulation or
reduced-ﬂuence V-PDT, depending on the location of these
polyps. These data thus conﬁrms the observed, inefﬁciency of anti-
VEGF monotherapy in PCV.
Summarizing, anti-VEGF monotherapy in PCV is not as efﬁcient
as it is in wet AMD, and requires the combination with other
treatments like PDT or thermal laser photocoagulation.
8. Combination therapies in the treatment of PCV
PDT in combination with other treatment modalities for neo-
vascular AMD has been extensively investigated in in vivo modelsand in clinical trials (Gomi et al., 2010; Lai et al., 2008; Saito et al.,
2012; Weiss et al., 2012). Angio-occlusive photodynamic therapy,
besides the desired closing of the targeted CNV, also can damage
and close the normal choroidal capillaries to some extent, thus
causing both hypoxia and inﬂammation. This, in turn, can lead to
reperfusion of the closed CNV, as well as regrowth of new CNV, and
hence the necessity of retreatment. The closure of neovasculature
by the combination of PDT with anti-angiogenic compounds thus
can prevent recurrent neovascularization. Further addition of cor-
ticosteroids will help to prevent inﬂammation, and may provide an
effective multilevel treatment for both AMD and PCV. Unique
characteristics in the pathogenesis of PCV contribute to disease
development and can be potential targets for intervention. To date,
there is only limited information on combination therapy for PCV
that is refractory to anti-VEGF therapy. The recent studies that show
PCV being refractory to anti-VEGF therapy however suggest that
the development of PCV is less likely, than for instance exudative
AMD, to be strongly dependent on VEGF-related pathways. Bev-
acizumab was found to decrease the amount of exudation associ-
ated with PCV, but the results of this anti-VEGF monotherapy were
not anywhere near as promising as those obtained in the treatment
of wet AMD (Gomi et al., 2008; Imamura et al., 2010; Lai et al., 2008;
Sridhar et al., 2013). This is possibly due to the fact that in PCV one
may deal with more mature vasculature than in the case of wet
AMD, and there are genetic differences, like for instance in the
elastin gene downregulation in AMD and upregulation in PCV,
which may be related to the aneurysm-like polypoidal structures.
Kokame et al. in a trial of monthly intravitreal ranibizumab
(0.5 mg) injections for PCV, reported the stabilization of vision at 6
months in 12 eyes (Kokame et al., 2010), as well as resolution of
subretinal hemorrhage and a decrease in macular edema. More-
over, polypoidal lesions decreased in 33% of eyes, but branching
choroidal vessels were still present.
Presently, in order to investigate the safety and efﬁcacy of a high
dose ranibizumab (2.0 mg) in PCV patients, a phase II clinical trial
(PEARL2) is recruiting patients (2010). The results are pending and
are expected in 2013.
Due to the limited effectiveness of the anti-VEGF treatment by
itself in PCV, combined therapymight be an optionwhen persistent
or recurrent exudative character of the lesions is observed post
anti-VEGF treatments.
8.1. PDT and anti-VEGF targeting
In PDT of PCV, the mechanism of photothrombosis causes
regression of the polyps and allows the gradual improvement of the
pathological features. Combining PDT with an anti-VEGF agent can
potentially create a synergistic effect that would (i) help to induce
polyp regression, (ii) reduce ﬂuid leakage and (iii) reduce inﬂam-
mation. There are several studies reporting promising results on
PDT combined with anti-VEGF treatment (see Fig. 5 for examples of
OCT and color fundus images). Selected trials are summarized
below and in Table 3. The EVEREST trial was the only randomized
controlled clinical trial including a set of well-deﬁned ICGA criteria
for PCV (Koh et al., 2012). 61 Asian patients were randomized to
either V-PDT (standard ﬂuence), or ranibizumab 0.5 mg, or the
combination of the two. The primary endpoint was the proportion
of patients with ICG-assessed complete regression of polyps at
month 6. At Month 6, all three treatment groups showed visual
acuity gain. In the ranibizumab monotherapy group, visual acuity
improvements were observed despite the presence of polyps. This
ﬁnding may be attributed to the anti-permeability effects of rani-
bizumab, thereby decreasing retinal thickening and exudate accu-
mulation. V-PDT combined with ranibizumab 0.5 mg or V-PDT
alone were both superior to ranibizumab monotherapy (77.8% and
Fig. 5. Multimodal imaging, comprising color fundus photography, OCT, ﬂuorescein and indocyanine green angiography are essential for the diagnosis and management of PCV, as
illustrated by this case: (A) Color fundus image with submacular hemorrhage and bi-lobed large hemorrhagic pigment epithelial detachments, surrounding neurosensory
detachment and subretinal lipid exudation occupying almost the entire left macula. (BeD) Pre-treatment OCT of the macula showing retinal thickening, sub-RPE elevation and
neurosensory ﬂuid. (E) Color fundus image 3 months after a single application of combination treatment of v-PDT and ranibizumab, showing complete resolution of pigment
epithelial detachments, macular hemorrhage and neurosensory detachment, and restoration of the normal macular architecture with corresponding improvement in visual acuity.
(FeH) Post-treatment OCT showing resolution of macular lesions as observed on color fundus photography. Repeat ICG post treatment showed resolution of the PCV complex, and
repeat treatment was not required.
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polyps in this 6-month study in patients with symptomatic macular
PCV. Longer term studies with larger patient populations are
required to assess the efﬁcacy of the treatments in achieving
complete regression of polyps and its correlationwith visual acuity,
and to evaluate the impact of concomitant V-PDT or ranibizumab
on decreasing the number of ranibizumab injections or V-PDT
interventions, respectively.
In the study reported by Ruamviboonsuk et al. (Ruamviboonsuk
et al., 2010) 12 eyes diagnosed with PCV were treated with V-PDTcombined with three monthly intravitreal ranibizumab (IVB) in-
jections. The patients were monitored monthly with measure-
ments of best-corrected visual acuity (BCVA) and OCT for 1 year. At
that time point, the mean BCVA change from baseline was þ12.3
letters and in all patients regression of polyps without recurrence
was observed. This combination therapy, however, did not reduce
the number of patients who required re-treatment over the 1 year
follow-up, when compared to data in the studies of V-PDT alone.
Also Gomi et al. reported superior results in PCV patients treated
with V-PDTcombinedwith IVB injection (1.25mg) as compared to
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subretinal hemorrhage within 1 month from the initial treatment
was signiﬁcantly lower in the combined therapy group than in the
PDT monotherapy group. Combined treatment decreased the rate
of PDT-related hemorrhage but did not affect the recurrence of the
lesions (Gomi et al., 2010).
It is worth mentioning that the optimal time interval between
intravitreal injection of anti-VEGF agents and PDT is still contro-
versial. Sato et al. reported on efﬁcient treatment of patients
receiving 1.25 mg intravitreal bevacizumab 7 days prior to V-PDT
(Sato et al., 2010) where at 12 month the mean BCVA improvement
from baseline was 2.69 lines. In a retrospectively reviewed study of
28 patients treated with 3 monthly intravitreal injections of rani-
bizumab (0.5 mg) and V-PDT performed 1 or 2 days after the ﬁrst
injection of ranibizumab (Saito et al., 2012) and a follow up of 12
months, the mean visual acuity levels improved from 0.33 at
baseline to 0.61. The mean improvement in best-corrected visual
acuity from baseline was 2.65 lines, and the central retinal thick-
ness decreased by two-fold. Administration of a ranibizumab in-
jection 2 days before PDT achieved signiﬁcantly better visual
outcomes compared with administration of the injection 7 days
before PDT (Sato et al., 2013). Combined intravitreal ranibizumab
and V-PDT maintained or improved visual acuity and reduced the
exudation without adverse events.
In another trial, patients initially subjected to whole-lesion V-
PDT combined with IVB were retreated with reduced-ﬂuence V-
PDT (at reduced spot size) þ IVB, or by thermal laser
photocoagulation þ IVB (Jeon et al., 2013). At year 3 after the ﬁrst
V-PDT þ IVB, the mean number of combination treatments (V-
PDT þ IVB) was 1.6 and IVB 5.9 courses, as compared to V-PDT
monotherapy. The results were favorable for the combination
group in improving or stabilizing visual acuity and reducing cu-
mulative V-PDT exposure. Only ﬁve eyes (12.5%) required focal
laser treatment for extrafoveal polypoidal lesions during follow-up.
Reduced-ﬂuence V-PDT (with a light dose of 25 J/cm2 delivered
over 83 s, and with an irradiance of 300 mW/cm2) combined with
IVB (1.25 mg) was reported recently by Sagong et al. (Sagong et al.,
2012) in sixteen patients with PCV. At 12 months, the visual acuity
improved in 56% of the eyes by 3 lines or more, was stable in 37% of
eyes, and decreased in 1 eye because of the recurrence of polyps.
Reduced-ﬂuence V-PDT combined with IVB for PCV seemed to be
effective in improving vision and reducing complications. Similar
promising results were reported recently using reduced-ﬂuence
V-PDT (light delivery over 70 s) followed 48 h later by intra-
vitreal ranibizumab (0.5mg) (Ricci et al., 2012). Yoshida et al. (2013)
reported on the 2-year results of reduced-ﬂuence V-PDT com-
bined with intravitreal ranibizumab. The BCVAs were maintained
in 13 of 14 PCV eyes at month 24 and the central foveal thickness
was decreased.
Summarizing, the combination therapy between Visudyne-
PDT and an anti-VEGF antibody or antibody fragment showed
encouraging results including improved vision, the reduced inci-
dence of subretinal hemorrhage, as well as the reduced recurrence
of polyps when compared to PDT monotherapy for PCV. According
to Koh et al. (Koh et al., 2013) the combination of V-PDT with
ranibizumab should be considered in eyes diagnosed with leakage
from the branching vascular network and the polyps, and also for
visible exudation associated with pigment epithelial detachment
(PED). V-PDT combined with ranibizumab should also be
considered when ICGA results do not permit clearly to distinguish
between PCV and CNV. The combination treatment would also
ensure the optimal treatment in the cases of the co-existence of
these two conditions (Brown et al., 2006; Koh et al., 2013). Com-
bination therapy efﬁcacy might also depend on previous unsuc-
cessful therapy and the possibility that resistance to the appliedtreatment developed (Tomita et al., 2012). Thus PDT combined with
ranibizumab led to signiﬁcant visual recovery in treatment-naïve
eyes with PCV, but not in eyes with PCV that had demonstrated
recurrence after previous PDT.
8.2. PDT combined with anti-inﬂammatory compounds
PDT destroys existing neovessels effectively acting as a “CNV
eraser”, and can be combined with an anti-VEGF strategy aimed at
inhibiting further neovessel growth and leakage. This combination
can be further extended by the addition of corticosteroids, which
will have an anti-inﬂammatory and anti-ﬁbrosis effect. Thus, by
affecting separate pathways it is not unreasonable to hope for
possible synergies that lead to a better overall treatment outcome.
Whereas promising results of V-PDT in combinationwith anti-
inﬂammatory compounds were reported in AMD (Saito et al.,
2009), this treatment modality did not seem to be so efﬁcient in
PCV patients. A retrospective analysis of PCV patients who under-
went V-PDT with or without intravitreal triamcinolone acetonide
(IVTA), with a follow-up of 2 or more years, was reported (Lai et al.,
2010). Twenty-seven eyes were analyzed, with 12 eyes treated by
PDT monotherapy and 15 eyes treated by combined V-PDT with
IVTA. PDT reduced the risks of visual loss in patients with symp-
tomatic PCV in the short term, but the effect was not sustained after
1 year. The adjunctive use of IVTA during PDT did not appear to
result in additional beneﬁt in the PDT treatment of PCV.
8.3. Triple therapy
To date, there is only one report with a long-term evaluation of
the combination therapy involving V-PDT, anti-VEGF and an anti-
inﬂammatory agent (Nakata et al., 2013) for the treatment of PCV.
The gain of visual acuity was reported in almost 42% of patients
treated with the triple therapy, and only in 12% in the V-PDT
group. Moreover, in the triple therapy group, the retreatment-free
period was longer and the vitreous hemorrhage was reduced as
compared to that in the V-PDT monotherapy group. Further long-
term studies are necessary to optimize this promising triple ther-
apy protocol for treating PCV.
9. Conclusions and future directions
Evidence based guidelines for the diagnosis and management of
PCV have recently been published (Koh et al., 2013). These guide-
lines include the use of indocyanine green angiography to identify
the early phase nodular hyperﬂuorescence. The subsequent treat-
ment for the juxtafoveal and subfoveal polyps is by ICG-guided PDT,
possibly combined with three 0.5 mg ranibizumab injections,
month apart, which is to be repeated if the polyps do not regress
completely. The current opinion for optimal PCV treatment is based
on clinical experience and a number of intermediate size case se-
ries. One question that remains is whether the more selective tar-
geting of choroidal neovascular membranes would improve the
therapeutic outcome of PDT, and thus lead leading to reduced
retreatment rates (Madar-Balakirski et al., 2010). The current use of
PDT, both in AMD and PCV, is drivenmainly by its combinationwith
other treatment strategies, thus trying to affect distinctly separate
pathways. An additional problem when making treatment de-
cisions in PCV management is the branching vascular network that
feeds the polyps. This branching vascular network can continue to
persist or even proliferate after thermal laser treatment or photo-
dynamic ablation of the polyps, and thus may ﬁnally cause new
leakage.
Currently, a frequent strategy that appears in AMD clinical trials
is the use of receptor tyrosine kinase inhibitors, e.g. pazopanib
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treatment of AMD in the ADVANCE trial (A Randomized, Double-
Masked, Multicenter, phase I/II Study of the Safety of Vatalanib
Administered to Patients With Predominantly Classic, Minimally
Classic or Occult With no Classic Subfoveal CNV Secondary to AMD)
(NCT00138632).
Direct interference with endothelial cell biology, independent of
growth factor stimulation, is also a preferred strategy of anti-
angiogenesis. Volociximab, an a5b1 antagonist, is a high-afﬁnity
monoclonal antibody binding to a5b1 integrin. This compound
blocks the binding of endothelial cells to ﬁbronectin. A phase I trial
to establish the safety, tolerability and the pharmacokinetics proﬁle
of Volociximab in CNV secondary to AMD is completed and results
are pending (NCT00782093). JSM6427 is a small molecule antag-
onist selective for a5b1integrin. It is currently under evaluation in a
Phase I clinical trial in patients with neovascular AMD
(NCT00536016).
Another strategy is targeting the mammalian target of rapa-
mycin (mTOR) with sirolimus. The mammalian target of rapamycin
is a protein kinase that regulates cell growth and metabolism in
response to changes in the environment. A phase II, randomized,
multicenter study (EMERALD) is currently recruiting patients with
wet AMD for a phase II study of an ocular sirolimus formulation in
combination with ranibizumab (NCT00766337).
These above-mentioned studies show the situation in AMD
treatment, however such data are not available for PCV. However, it
would at least some of these trials may well be worthwhile
repeating for the case of PCV. One of the problems in this case will
be the absence of a valid animal model for PCV to do the preclinical
evaluations.
Another way to effectively and selectively close neo-
vascularization might be through treatment with vascular disrupt-
ing agents (VDAs) targeting tubulin. Tubulin is a protein dimer
composed of a and b subunits that form microtubules, which are
essential to cellular functions likemitosis, transport, and cytokinesis
(McKeage and Baguley, 2010). VDAs reversibly depolymerize the
microtubules, leading to a shut down of the blood vessels. Zybrestat
(Fosbretabulin,Oxigene Inc.) is a small molecule combretastatin-A4-
phosphate prodrug that is converted to combretastatin inside
endothelial cells. Once activated within the endothelial cells, it
causes rapid collapse and necrosis of the vasculature. The FAVOR
trialwas a phase II study investigating theuse of a single intravenous
injection of Zybrestat at differentdoses (15e45mg/m2) compared to
placebo in Asian patients with PCV, followed by imaging of the
retinaondays 2, 8,15, and28. Theprimaryobjective of the studywas
to observe a change in the number of polyps frombaseline following
the administration of Zybrestat. The data showed that Zybrestatwas
well tolerated, however in the patients with decreased polypoidal
activity, the reduction in subretinal ﬂuid and retinal edema was
insigniﬁcant (2012).
Animal models of PCV still do not exist. Whereas part of the
genotype has been reported on, there remain a number of prob-
lems. First, knockout mice with the known genotype alterations
may not be subject to the same phenotypic disease severity as
humans, which have a much longer lifespan. Second, the human
eye’s retina, with its high resolution color vision in the macula,
where high light intensity signals are rapidly processed by cones,
and the rest of the eye where rods dominate the lower resolution
and low intensity night vision, is unlike the mouse’s retina. Our
retina furthermore has an extremely high density of photorecep-
tors, as well as a high photoreceptor/RPE cell ratio. Nevertheless,
knock-in and knock-out animal models, with induced mutations,
are expected in the near future to be of help in better under-
standing of the disease to be studied and the development of new
treatments, as well as possible prevention strategies.One therapeutic approach to prevent possible causes of AMD or
PCV may be the prevention of all-trans-RAL associated retinal
degeneration. Preclinical studies conducted in a mouse model of
light-induced retinal regeneration, in order to ﬁnd selective in-
hibitors such as fenretinide and 13-cis-retinoic acid, or retinyl-
amine, that can regulate the ﬂux of retinoids through the visual
cycle already gave promising results (Maeda et al., 2006; Radu et al.,
2005). One may speculate that such a strategy used for dry-type
AMD, could possibly also help to prevent, or at least to some
extent, slow down PCV development. The use of protective sun-
glasses and anti-oxidants should then also be considered, as better
understanding of the effects of light on the eye would help to make
a better choice of the interior light sources that to some extent can
inﬂuence the development of eye disorders. Such an approach may
help to, at least partially, prevent the progression of retinal
dysfunction before visual acuity is affected.
In conclusion, photodynamic therapy with Visudyne com-
bined with anti-VEGF therapy represents, at this point of time, the
best treatment modality for PCV.
PCV is not as well treated by anti-VEGFs as is wet AMD. V-PDT
seems to work better in PCV than in wet AMD. V-PDT in PCV gives
good results for VA, suppressed leakage, as well as vessel disap-
pearance. In newly diagnosed PCV patients who achieved initial
positive responses (polyp regression) following V-PDT only,
additional treatment would not be required for at least 1 year for
most of patients. For persistent or recurrent lesions, retreatment
should be adapted to individual features since the branching
network may be not destroyed completely. V-PDT combined with
anti-VEGFs works better for PCV than V-PDT alone, or anti-VEGFs
alone, giving good short-term results (up to two years). Still the
photodynamic procedure itself might be improved by for instance
the use of delayed light delivery after the Visudyne injection.
Moreover, future molecular investigations are still needed to
further identify the genetic differences between PCV and AMD. Also
the relative timing of anti-VEGF and V-PDT still needs to be
optimized. According to preliminary data, same-day administration
may result in less endophthalmitis and uveitis compared with
treatments delivered days apart. It is worth emphasizing the
EVEREST trail, where both V-PDTand V-PDTþ ranibizumabwere
efﬁcient in achieving polyp regression. Triple therapy data seem to
indicate that it offers a good safety proﬁle, potentially lower cost, as
compared with therapies that must be administered more
frequently. More long-term investigation is needed to conﬁrm its
superiority vs. V-PDT þ anti-VEGFs.Conﬂict of interest
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